Founded in 1986 by PV Ramprasad Reddy and K Nityananda Reddy, Aurobindo Pharma is one the largest pharmaceutical companies in India. Its operations began in 1988 with a single unit producing semi-synthetic penicillin (SSP) in Puducherry. The company went public in 1992 and was listed on the stock exchanges in 1995.
The market capitalisation of Aurobindo Pharma Limited is over ₹63,800 crore as of December 28, 2023. Aurobindo Pharma share price has gained over 14% in three years.
Business operations
Aurobindo Pharma specialises in producing semi-synthetic penicillin and has a strong presence in various essential medical areas such as cephalosporins, antivirals, cardiovascular and gastroenterology. It is the leading provider of semi-synthetic penicillin medications. The company's product range covers formulations like those for cardiovascular, gastroenterology, antiretrovirals and anti-infectives.
Notable formulations include trandolapril, captopril, and benazepril hydrochloride, among others. It also manufactures active pharmaceutical ingredients and organic intermediates like desmethyl azithromycin, methenamine and benzimidazole.
Aurobindo Pharma operates 11 units for APIs/intermediates and 15 units (10 in India, three in the USA, one in Brazil and one in Portugal) for formulations, strategically designed to cater to both established and emerging market needs.
In the United States, Aurobindo Pharma operates across oral medications, injectables, over-the-counter and branded oncology segments. It has submitted 774 ANDAs (abbreviated new drug applications) and received 565 final approvals as of March 31, 2023.
In Europe, Aurobindo Pharma has established its presence in 10 countries with fully equipped pharmacies, hospitals, and sales infrastructure for tenders.
Its business model heavily relies on its input. A total of ₹1,411.5 crore was allocated towards research and development (R&D). This initiative led to the submission of 774 Abbreviated New Drug Applications (ANDAs), 276 Drug Master Files (DMFs) and 813 filed patent applications. The company filed 4,359 formulation dossiers and 3,718 API (Active Pharmaceutical Ingredient) product submissions in various markets outside the USA.
As an integrated pharmaceutical company, Aurobindo Pharma ranks among India's top pharmaceutical firms in terms of combined revenues. Exporting to over 150 countries globally, approximately 90% of its revenue comes from international ventures, serving esteemed multinational clientele.
Aurobindo Pharma’s facilities have approvals from major regulatory bodies across the world such as USFDA, EU GMP, UK MHRA, Health Canada, WHO and Brazil ANVISA.
Aurobindo Pharma operates five research centres spanning 16,000 square meters, along with two additional R&D centres in the USA. The company has a team of over 1,560 in-house scientists and analysts for product development.
Aurobindo Pharma Financial Highlights
- Revenue: Aurobindo Pharma reported revenue of ₹34,145.17 crore in FY26 vs ₹32,345.58 crore in FY25. It showed an increase of 5.56% on a yearly basis.
- Operating Profit: Aurobindo Pharma reported an operating profit of ₹5,111.85 crore in FY26 vs ₹5,066.29 crore in FY25. It showed an increase of 0.90% on a year-on-year basis.
- Net Profit: Aurobindo Pharma reported a net profit of ₹3,502.97 crore in FY26 vs ₹3,483.57 crore in FY25. It showed an increase of 0.56% on a yearly basis.
Aurobindo Pharma Quarterly Result Highlights
- Aurobindo Pharma reported revenue of ₹8,970.38 crore in Mar 2026, compared with ₹8,833.54 crore in Dec 2025, representing an increase of 1.55% on a quarter-on-quarter (QoQ) basis.
- Aurobindo Pharma reported an operating profit of ₹1,290.61 crore in Mar 2026, compared with ₹1,338.52 crore in Dec 2025, representing a decrease of 3.58% on a quarter-on-quarter (QoQ) basis.
- Aurobindo Pharma reported a profit of ₹920.84 crore in Mar 2026, compared with ₹909.80 crore in Dec 2025, reflecting an increase of 1.21% on a QoQ basis.
- The earnings per share (EPS) of Aurobindo Pharma stood at ₹59.81 during Mar 2026.
